BERGEN, Norway, August 22, 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announcedtoday that additional clinical data of
bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small
Cell Lung Cancer (NSCLC) have been recently published and accepted for
presentation at two upcoming international oncology conferences:

  · Comprehensive results from the investigator led trial of bemcentininb +
docetaxel in previously treated NSCLC patients (Study BGBIL005) were published
in the August 2023 issue of Lung Cancer. "Phase 1 trial of bemcentinib (BGB324),
a first-in-class, selective AXL inhibitor, with docetaxel in patients with
previously treated advanced non-small cell lung cancer." Lung Cancer 182 (2023)
The trial was led by David Gerber, MD., Professor at the UT Southwestern Harold
C. Simmons Comprehensive Cancer Center.
  · The abstract "Bemcentinib + Pembrolizumab show promising efficacy in
metastatic NSCLC harbouring mutations associated with poor prognosis:
Exploratory sub-analysis from the BGBC008 trial (NCT03184571)" has been accepted
for posterpresentationat the SITC 38th Annual Meeting, to be held November 3-5,
2023,in San Diego, CA (Abstract #598).
  · The abstract "Final top-line results of the BGBC008 phase 2, multicenter
study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced
non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)"has been
accepted for poster presentation at the ESMO Congress 2023, to be held October
20-24, 2023, in Madrid, Spain (Abstract #5343)

"The accumulating evidence supporting the potential role of bemcentinib in NSCLC
aligns with our strategic focus on this disease where a large portion of
patients still have very poor clinical outcome from existing therapies" said
Martin Olin, Chief Executive Officer of BerGenBio. "The publication of data in a
prestigious peer reviewed publication and at ESMO and SITC provides us with the
opportunity to share our data with a broad audience of oncologists and key
opinion leaders in the field of NSCLC and the pharmaceutical industry."

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

This information is subject to the disclosure requirements pursuant to MAR
article 17 and section 5-12 of the Norwegian Securities Trading Act.